Patent number

Description

Assignee

Inventor

Date

US 11,286,468

Engineered CRISPR–Cas9 nucleases with altered and improved protospacer adjacent motif (PAM) specificities and their use in genomic engineering, epigenomic engineering, and genome targeting.

General Hospital Corp. (Boston, MA, USA)

Joung JK,

Kleinstiver B

3/29/2022

US 11,168,313

Engineered CRISPR from Prevotella and Francisella 1 (Cpf1) nucleases with altered and improved target specificity and their use in genomic engineering, epigenomic engineering, genome targeting, genome editing, and in vitro diagnostics.

General Hospital Corp. (Boston, MA, USA)

Joung JK,

Kleinstiver B

11/9/2021

US 11,072,782

A construct for epigenomic modification of genes composed of a Kruppel-associated box zinc finger protein or homologous; a DNA region capable of binding to the target gene or homologous; a human DNA methyltransferase DNMT3A or homologous and a murine DNA methyltransferase DNMT3L or homologous, wherein the components are linked to each other either directly or via at least one linker. The construct is a designer epigenome modifier that can be used to silence genes coding for a protein in leukocytes that avoids the internalization of human immunodeficiency viruses in immune cells.

Albert Ludwig University of Freiburg (Freiburg, Germany)

Cathomen T,

Mussolino C,

Cornu TI,

Mlambo T,

Nitsch S,

Alzubi J,

Romito M

7/27/2021

US 11,060,078

Engineered CRISPR–Cas9 nucleases with improved specificity and their use in genomic engineering, epigenomic engineering, genome targeting, and genome editing.

General Hospital Corp. (Boston, MA, USA)

Joung JK,

Kleinstiver B,

Pattanayak V

7/13/2021

US 10,676,735

Methods of using CRISPR–Cas9-based epigenomic editing systems for high-throughput screening of regulatory element function.

Duke University (Durham, NC, USA)

Gersbach CA,

Crawford GE,

Reddy TE,

Klann TS

6/9/2020

US 10,329,614

Methods for DNA sequencing and performing epigenomic analyses, including immobilizing a plurality of copies of a DNA molecule on a surface, stretching at least a portion of the immobilized DNA molecules, and sequencing at least a portion of the immobilized, stretched DNA molecules.

STC.UNM (Albuquerque, NM, USA)

Edwards JS

6/25/2019

US 9,023,819

A method for treating a subject having or suspected of having a disease or condition associated with aberrant hypomethylation of one or more genes in the subject, involving a tailored epigenomic modification of the subject using methylated polynucleotides directed to hypomethylated genes in the subject. Also, a medicinal composition for treating a subject having or suspected of having a disease or condition associated with aberrant hypomethylation of one or more genes in the subject, including methylated polynucleotides directed to hypomethylated genes in the subject, so as to result in a tailored epigenomic modification of the subject upon administration.

National Chung Cheng University (Chia-Yi, Taiwan)

Leu Y-W,

Hsiao S-H,

Huang TH-M

5/5/2015

  1. Source: United States Patent and Trademark Office (https://www.uspto.gov), Google Patents.